2026-04-01
Why biotech companies remain invisible despite strong science
Strong programs can still read as opaque when evidence is fragmented and nobody owns the narrative arc from mechanism to commercial intent.
Read →When the claims behind a deal are made explicit and tested against evidence, lean funds decide faster — and co-investors can inspect the same artifact.
Filter by strategic lens
2026-04-01
Strong programs can still read as opaque when evidence is fragmented and nobody owns the narrative arc from mechanism to commercial intent.
Read →2026-04-08
Conferences compress access; they do not replace durable evidence. The best programs treat both as parts of one system.
Read →2026-04-12
Mechanism pages work when they respect both scientific accuracy and the reader’s limited working memory.
Read →